{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:20:00Z","timestamp":1793020800875,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001763","name":"Australia-China Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacc.2024.05.014","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:20:07Z","timestamp":1723130407000},"page":"1123-1143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["2024 Update to the 2020 ACC\/AHA Clinical Performance and Quality Measures for Adults With Heart Failure"],"prefix":"10.1016","volume":"84","author":[{"given":"Michelle M.","family":"Kittleson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijah","family":"Breathett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boback","family":"Ziaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Blumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Diekemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Dorsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine Y.","family":"Jurgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateeti","family":"Khazanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Augustine","family":"Koromia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.05.014_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2005.03.011","article-title":"American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care","volume":"45","author":"Spertus","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.jacc.2010.09.009","article-title":"ACCF\/AHA new insights into the methodology of performance measurement: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Performance Measures","volume":"56","author":"Spertus","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib3","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.jacc.2020.07.023","article-title":"2020 ACC\/AHA clinical performance and quality measures for adults with heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures","volume":"76","author":"Heidenreich","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib4","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib7","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.014_bib8","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","article-title":"Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction","volume":"5","author":"Gaziano","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.amjcard.2014.05.062","article-title":"Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study)","volume":"114","author":"Maisel","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.014_bib16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib18","first-page":"647","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"8","author":"Prins","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.05.014_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","article-title":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program","volume":"52","author":"Fonarow","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib20","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.05.014_bib21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/phar.2091","article-title":"Guideline-directed medical therapy and survival following hospitalization in patients with heart failure","volume":"38","author":"Tran","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2024.05.014_bib22","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","article-title":"Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury","volume":"137","author":"Ahmad","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCHEARTFAILURE.107.736975","article-title":"Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial","volume":"1","author":"Anand","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.014_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ejhf.210","article-title":"Impact of worsening renal function related to medication in heart failure","volume":"17","author":"Brunner-La Rocca","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.136","article-title":"Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial","volume":"16","author":"Montero-Perez-Barquero","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib27","first-page":"350","article-title":"Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF Registry","volume":"7","author":"Peri-Okonny","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.05.014_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","article-title":"Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry","volume":"53","author":"Hernandez","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjmed.2014.11.036","article-title":"Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure","volume":"128","author":"Bhatia","year":"2015","journal-title":"Am J Med"},{"issue":"82","key":"10.1016\/j.jacc.2024.05.014_bib30","first-page":"e1","article-title":"Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"153","author":"Fonarow","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.05.014_bib31","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.05.014_bib32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2016.05.008","article-title":"Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure","volume":"129","author":"Sanam","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib34","first-page":"561","article-title":"Treatment initiation patterns, modifications, and medication adherence among newly diagnosed heart failure patients: a retrospective claims database analysis","volume":"22","author":"Deschaseaux","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jacc.2024.05.014_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib36","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib37","article-title":"Real-world analysis of guideline-based therapy after hospitalization for heart failure","volume":"9","author":"Wirtz","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.05.014_bib38","first-page":"2103","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control [published correction appears in N Engl J Med. 2017;377:2506]","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib39","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0000000000001052","article-title":"Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2024.05.014_bib40","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged\u00a0\u226575 years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.05.014_bib41","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.014_bib43","first-page":"933","article-title":"Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: insights from the Department of Veterans Affairs","volume":"11","author":"Hussain","year":"2023","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.05.014_bib47","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003552","article-title":"National differences in trends for heart failure hospitalizations by sex and race\/ethnicity","volume":"10","author":"Ziaeian","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2024.05.014_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006472","article-title":"Risk factors for heart failure: 20-year population-based trends by sex, socioeconomic status, and ethnicity","volume":"13","author":"Lawson","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib49","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2021.06.058","article-title":"Race and ethnicity in heart failure: JACC focus seminar 8\/9","volume":"78","author":"Pi\u00f1a","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib50","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2020.3654","article-title":"Trends in the prevalence of self-reported heart failure by race\/ethnicity and age from 2001 to 2016","volume":"5","author":"Rethy","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib52","series-title":"Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health: Commission on Social Determinants of Health Final Report","year":"2008"},{"key":"10.1016\/j.jacc.2024.05.014_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004052","article-title":"Neighborhood deprivation predicts heart failure risk in a low-income population of blacks and whites in the Southeastern United States","volume":"11","author":"Akwo","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2024.05.014_bib54","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.jacc.2018.02.077","article-title":"Cardiovascular disease and homelessness","volume":"71","author":"Baggett","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib55","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1161\/CIR.0000000000000767","article-title":"Addressing social determinants of health in the care of patients with heart failure: a scientific statement from the American Heart Association","volume":"141","author":"White-Williams","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjcard.2009.02.057","article-title":"Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF)","volume":"104","author":"Fonarow","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib57","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/jwh.2012.4107","article-title":"Gender and other disparities in referral to specialized heart failure clinics following emergency department visits","volume":"22","author":"Feldman","year":"2013","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.jacc.2024.05.014_bib58","first-page":"413","article-title":"African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure","volume":"6","author":"Breathett","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.05.014_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006214","article-title":"Identification of racial inequities in access to specialized inpatient heart failure care at an academic medical center","volume":"12","author":"Eberly","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib60","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s40615-018-0468-z","article-title":"Factors related to physician clinical decision-making for African-American and Hispanic patients: a qualitative meta-synthesis","volume":"5","author":"Breathett","year":"2018","journal-title":"J\u00a0Racial Ethn Health Disparities"},{"key":"10.1016\/j.jacc.2024.05.014_bib61","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.cardfail.2020.07.014","article-title":"Socioeconomic deprivation and heart failure mortality in the United States","volume":"26","author":"Bevan","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib62","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.cardfail.2015.05.013","article-title":"Heart failure in non-Caucasians, women, and older adults: a white paper on special populations from the Heart Failure Society of America Guideline Committee","volume":"21","author":"Colvin","year":"2015","journal-title":"J\u00a0Card Fail"},{"issue":"8","key":"10.1016\/j.jacc.2024.05.014_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","article-title":"Understanding the complexity of heart failure risk and treatment in black patients","volume":"13","author":"Nayak","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib64","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.117.029652","article-title":"Socioeconomic status and cardiovascular outcomes","volume":"137","author":"Schultz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib65","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib66","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10903-014-0098-4","article-title":"Potentially preventable hospitalizations for congestive heart failure among Asian Americans and Pacific Islanders in Hawai'i","volume":"17","author":"Sentell","year":"2015","journal-title":"J\u00a0Immigr Minor Health"},{"key":"10.1016\/j.jacc.2024.05.014_bib67","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1161\/CIR.0000000000000773","article-title":"Cardiovascular health in American Indians and Alaska Natives: a scientific statement from the American Heart Association","volume":"141","author":"Breathett","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib68","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","article-title":"Cardiovascular health in African Americans: a scientific statement from the American Heart Association","volume":"136","author":"Carnethon","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib69","first-page":"465","article-title":"Health status disparities by sex, race\/ethnicity, and socioeconomic status in outpatients with heart failure","volume":"6","author":"Khariton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.05.014_bib70","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIR.0000000000000071","article-title":"Status of cardiovascular disease and stroke in Hispanics\/Latinos in the United States: a science advisory from the American Heart Association","volume":"130","author":"Rodriguez","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib71","article-title":"Social determinants of health and 90-day mortality after hospitalization for heart failure in the REGARDS study","volume":"9","author":"Sterling","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.05.014_bib73","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2018.02.076","article-title":"Pregnancy outcomes in women with heart disease: the CARPREG II study","volume":"71","author":"Silversides","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib74","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41591-023-02416-2","article-title":"Pregnant and lactating women should be included in clinical trials for cardiovascular disease","volume":"29","author":"Assadpour","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022755","article-title":"Experiences of women with cardiac disease in pregnancy: a systematic review and metasynthesis","volume":"8","author":"Dawson","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2024.05.014_bib76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijcard.2017.03.092","article-title":"Pre-pregnancy counseling for women with heart disease: a prospective study","volume":"240","author":"Cauldwell","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib77","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/AOG.0000000000002439","article-title":"Subsequent pregnancy outcomes in patients with peripartum cardiomyopathy","volume":"131","author":"Codsi","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2024.05.014_bib78","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacc.2014.07.961","article-title":"Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy","volume":"64","author":"Elkayam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib79","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM200105243442101","article-title":"Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy","volume":"344","author":"Elkayam","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib80","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/ejhf.808","article-title":"Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy","volume":"19","author":"Hilfiker-Kleiner","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib81","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehs270","article-title":"Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology","volume":"34","author":"Roos-Hesselink","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.014_bib82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12872-018-0856-7","article-title":"Maternal and fetal prognosis of subsequent pregnancy in black African women with peripartum cardiomyopathy","volume":"18","author":"Yameogo","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2024.05.014_bib83","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejhf.1493","article-title":"Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"21","author":"Bauersachs","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib84","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jacc.2018.10.075","article-title":"Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review","volume":"73","author":"Halpern","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib85","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.014_bib86","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.014_bib87","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1038\/s41598-023-30700-1","article-title":"Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2024.05.014_bib88","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0735-1097(02)02937-6","article-title":"Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure","volume":"41","author":"Breithardt","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib89","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.amjcard.2017.07.023","article-title":"Functional mitral regurgitation predicts short-term adverse events in patients with acute heart failure and reduced left ventricular ejection fraction","volume":"120","author":"De la Espriella","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib90","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/01.CIR.0000065226.24159.E9","article-title":"Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure","volume":"107","author":"St John Sutton","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib91","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2007.01.026","article-title":"Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction","volume":"49","author":"Bhudia","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib92","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0002-8703(00)90036-X","article-title":"\u03b2-Blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol","volume":"139","author":"Capomolla","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.05.014_bib93","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa050666","article-title":"Long-term vasodilator therapy in patients with severe aortic regurgitation","volume":"353","author":"Evangelista","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib94","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2018.18077","article-title":"Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement","volume":"320","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.05.014_bib95","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib96","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/S0140-6736(15)60290-2","article-title":"5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial","volume":"385","author":"Kapadia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.014_bib97","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0002-9149(99)00059-4","article-title":"Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure","volume":"83","author":"Lowes","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib98","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0140-6736(15)60308-7","article-title":"5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial","volume":"385","author":"Mack","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.014_bib99","first-page":"652","article-title":"Evolution of functional mitral regurgitation and prognosis in medically managed heart failure patients with reduced ejection fraction","volume":"5","author":"Nasser","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.05.014_bib100","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib101","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1161\/CIRCULATIONAHA.110.009803","article-title":"Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk","volume":"124","author":"van Bommel","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib102","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/eurjhf\/hfp051","article-title":"Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction","volume":"11","author":"Agricola","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib103","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.amjcard.2015.11.010","article-title":"Effect of QRS narrowing after cardiac resynchronization therapy on functional mitral regurgitation in patients with systolic heart failure","volume":"117","author":"Karaca","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib104","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/ehjci\/jeab095","article-title":"99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis","volume":"22","author":"Quarta","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.05.014_bib105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-019-0193-9","article-title":"Two types of amyloidosis presenting in a single patient: a case series","volume":"9","author":"Sidiqi","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jacc.2024.05.014_bib106","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib107","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.05.014_bib108","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis","volume":"75","author":"Hanna","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib109","first-page":"709","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.05.014_bib110","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.05.014_bib111","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib112","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.014_bib113","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/europace\/euaa094","article-title":"Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator","volume":"22","author":"Kim","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.05.014_bib114","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib116","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.014_bib117","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724072887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724072887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T20:01:39Z","timestamp":1758139299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724072887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":113,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0735109724072887"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.05.014","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2024 Update to the 2020 ACC\/AHA Clinical Performance and Quality Measures for Adults With Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier. All rights are reserved, including those for text and data mining, AI training, and similar technologies","name":"copyright","label":"Copyright"}]}}